Evidence map›Paper›PMID 39909904›Full record

GuidelineAnnals of hematology2025

Use of hydroxyurea in French-speaking Sub-Saharan Africa.

Jean-Benoît Arlet, Françoise Bernaudin, Indou Deme-Ly, Binta Coulibaly, Anne Corbasson, Ibrahima Diagne, Dapa Diallo, Saliou Diop, Charlotte Eposse, Frédéric Galacteros and 8 more

Abstract readConsensus StatementPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jean-Benoît ArletDepartment of Internal Medicine, Georges Pompidou European Hospital, AP-HP, French National Reference Center for Sickle Cell Anemia, Thalassemia, Other Rare Red Blood Cell Disorders and Erythropoiesis, Paris, and Université Paris-Cité, Paris, France. jean-benoit.arlet@aphp.fr.
Françoise BernaudinPediatric Department Sickle Cell Referral Center, Intercommunal Hospital of Créteil, 94000, Creteil, France.
Indou Deme-LyCheikh Anta Diop University, Dakar, Senegal.
Binta Coulibaly, Francfort-Sur-Le-Main, Germany.
Anne CorbassonDepartment of Internal Medicine, Georges Pompidou European Hospital, AP-HP, French National Reference Center for Sickle Cell Anemia, Thalassemia, Other Rare Red Blood Cell Disorders and Erythropoiesis, Paris, France.
Ibrahima DiagneCooperation and Pedagogic Innovation, Gaston Berger University of Saint-Louis, Saint-Louis, Senegal.
Dapa DialloHematology at the Faculty of Medicine and Odontostomatology of the University of Science, Techniques and Technologies (USTTB), , Bamako, Mali.
Saliou DiopDepartment of Hematology, University Cheikh Anta Diop, Dakar, Senegal.
Charlotte EposseDouala Laquintinie Hospital, Faculty of Medecine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.
Frédéric GalacterosUnité Des Maladies Génétiques du Globule Rouge (UMGGR), GHU Henri-Mondor, AP-HP Et U-PEC, Médecine Interne, Paris, France.
Olivier HermineDepartment of Hematology, Necker-Enfants Malades Hospital, AP-HP, Paris, France.
Eléonore KafandoLaboratory of Hematology, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Agnès LainéInstitut Des Mondes Africains, Aubervilliers, France.
Mariane de MontalembertService de Pédiatrie Générale, Hôpital Necker, Assistance Publique -Hôpitaux de Paris, Paris, France.
Constant VodouhéAssociation DORYS, Strasbourg, France.
Ahoefa VovorFaculty of Health Sciences, Lomé, Togo.
Brigitte RanqueDepartment of Internal Medicine, Georges Pompidou European Hospital, AP-HP, French National Reference Center for Sickle Cell Anemia, Thalassemia, Other Rare Red Blood Cell Disorders and Erythropoiesis, Paris, and Université Paris-Cité, Paris, France.
Léon TshiloloDepartment of Pediatrics, Centre Hospitalier Monkole, Kinshasa, Democratic Republic of Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hydroxyurea is a save, affordable and essential medicine for sickle cell disease (SCD), reducing painful crises and mortality. To foster the prescription of hydroxyurea for patients with SCD in sub-Saharan African countries, the scientific advisory board of Drep.Afrique, a non-governmental organization dedicated to SCD in Africa, has developed a therapeutic guideline well suited to conditions on the ground. These guidelines answer three essential questions: which patients should be prioritized for treatment with hydroxyurea, which dose should be used, and what follow-up should be implemented in those low-resources countries? The guidelines are given as in a concise document for easy use by practitioners on the ground, available in English and in French.

Indexed as

Anemia, Sickle CellAntisickling AgentsHydroxyureaAfrica South of the SaharaHumansAntisickling AgentsHydroxyureaAfricaFrench-speaking countriesGuidelinesHydroxyureaSickle cell disease

Identifiers

PMID39909904
PMCPMC11971222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.